Xilio Therapeutics Clears FDA Hurdle for XTX501, Advances Pipeline with $136M Cash Runway — Xilio Therapeutics, Inc.

Event summary

FDA cleared Xilio's IND application for XTX501, a bispecific PD-1/masked IL-2 therapy, advancing it to Phase 1/2 trials.
Company expects to initiate dosing in metastatic NSCLC and select solid tumors in H2 2026, with initial data anticipated in H2 2027.
IND-enabling studies progress for CLDN18.2 and PSMA+STEAP1 programs; IND submissions planned for H2 2027.
$136M cash runway extends into Q1 2028, with potential $36.2M from Series C warrants and up to $31M in AbbVie milestones.

The big picture

Xilio's FDA clearance for XTX501 positions it in the competitive immuno-oncology space, where next-generation multi-specific therapies aim to overcome limitations of current treatments. The company's masking technology could differentiate its pipeline, but success hinges on clinical validation and strategic partnerships with AbbVie and Gilead.

What we're watching

Clinical Execution: The pace at which XTX501 advances through Phase 1/2 trials will determine its potential as a foundational therapy for solid tumors.
Pipeline Momentum: Whether the CLDN18.2 and PSMA+STEAP1 programs meet IND submission timelines in H2 2027 could signal Xilio's ability to sustain multi-specific I-O pipeline progress.
Financial Flexibility: How Xilio manages its $136M cash runway and potential additional funding from warrants/milestones will impact its operational agility through 2028.